Japanese pharmacists not Rxing generics

26 April 2009

Japanese pharmacists in the insurance sector appear not to be dispensing generic drugs, even though physicians have approved the shift from  branded to copy medicines in prescriptions, according to the detailed  results of the generic drug usage survey conducted by Japan's Ministry  of Health, Labor and Welfare, which has recently been submitted to the  Chuikyo (Central Social Insurance Medical Council).

Preliminary results in the insurance pharmacy survey were revealed at  the March Chuikyo meeting (Marketletter April 6). According to the  final findings, the generics dispensing rate has steadily increased.  In the survey, 65.6% of pharmacists received prescriptions with no  signature in the column "Do not change to generic drug." Among them,  74.8% did not change to a copy. 10.2 % and 8.9% of pharmacies also did  not switch because the generics as prescribed were not listed in the  National Health Insurance list and patients did not want the  alternatives, respectively, while only 6.1% of pharmacies shifted even  one branded product to a copy version.

33.5% of pharmacies said: "we are not eager to dispense generic drugs,"  with 40.2% (plural answers allowed) of them noting that the quality of  generic drugs was not assured and stable supply systems were not  established, respectively, while 36.7% said "efficacy is doubtful."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight